PTAFR and melanoma: To evaluate the role of PAF-R in the progression of melanoma, the B16-PAF-R and B16-MSCV cells were treated with the non-metabolizable PAF-R agonist, CPAF, at different doses and time points prior to the assessment of cell proliferation.